<DOC>
	<DOCNO>NCT00054808</DOCNO>
	<brief_summary>Eligible patient low- intermediate-grade Non-Hodgkin 's Lymphoma ( NHL ) progress standard chemotherapy . Patients receive gallium nitrate 300 mg/m2/day continuous IV infusion 7 consecutive day use portable infusion pump . Hospitalization require . Stable respond patient receive additional gallium nitrate infusion every 3 week time disease progression , maximum total 8 infusion , 2 cycle complete remission document .</brief_summary>
	<brief_title>Phase II Gallium Nitrate Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>This study seek define role gallium nitrate specific population patient expect received prior therapy . Preliminary clinical study suggest substantial evidence antitumor activity patient relapse refractory non-Hodgkin 's Lymphoma treat gallium nitrate .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gallium nitrate</mesh_term>
	<criteria>Low intermediategrade NHL use International Working Formulation , subtypes IWF AG : Using Updated REAL/WHO Classification , follow pathologic subtypes eligible : Small lymphocytic lymphoma Lymphoplasmacytic lymphoma/immunocytoma Follicular lymphoma Diffuse large Bcell lymphoma Peripheral Tcell lymphoma , otherwise characterize Progression disease follow treatment standard chemotherapy Bidimensionally measurable disease Performance Status : ECOG &lt; = 2 Patients mantle cell lymphoma mycosis fungoides eligible Patients know history CNS metastasis eligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Gallium Nitrate</keyword>
	<keyword>Ganite</keyword>
	<keyword>NHL</keyword>
	<keyword>Relapsed</keyword>
</DOC>